Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 11:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Breast Cancer
Interventions: AZD9496 (Reference), AZD9496 Variant A, AZD9496 Variant B, AZD9496 Variant C, AZD9496 Variant D; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Surgical Stress Response, Stress Physiological, Stress Physiology, Stress Psychological, Breathing Techniques, Breathing Exercises, Hypothalamic Pituitary Adrenal, Relaxation, Relaxation Therapy, Cortisol, Postoperative Pain, Postoperative Anxiety, Postoperative Depression, Quality of Recovery (QoR-15)
Interventions: A 5-minute Asynchronous Breathwork Intervention, A 5-minute Asynchronous Card Game Video; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 65 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Coronary Heart Disease
Interventions: DFV890, DFV890 Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Northridge, California • Boca Raton, Florida • Jacksonville, Florida + 3 more

Conditions: Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection
Interventions: PET Tracer, MRI Tracer, 3T PET/MRI; Drug · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: ZEN-3694, Testosterone cypionate, Enzalutamide, Luteinizing hormone-releasing hormone (LHRH) analogue; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pharmacokinetics
Interventions: Natrunix, Placebo; Biological
Lead sponsor: XBiotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Insomnia
Interventions: Sleep Using Mentored Behavioral and Environmental Restructuring; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteoarthritis
Interventions: VX-150, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 12
States / cities: San Diego, California • West Palm Beach, Florida • Marietta, Georgia + 9 more

Conditions: Asthma, Bronchoconstriction
Interventions: Levalbuterol HFA MDI, Racemic Albuterol; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 5
States / cities: Los Angeles, California • Signal Hill, California • Denver, Colorado + 2 more

Conditions: Obesity, Healthy Lifestyle
Interventions: Lifestyle Intervention, Dasatinib 100 MG, Quercetin 1000mg, Placebo, Abdominal adipose tissue biopsy; Other · Drug · Procedure
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy
Interventions: IMBRUVICA (Treatment A), Ibrutinib (Treatment B); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Gastroparesis
Interventions: Gastric Electrical Stimulator, Enterra, Medtronics, Inc.; Device
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Healthy Participants
Interventions: Swedish Massage Therapy, Light Touch Control; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 64 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hearing Loss
Interventions: electrical stimulation, optical stimulation, combined optical and electrical stimulation; Device · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Coral Gables, Florida • Columbia, Missouri

Conditions: Right Bundle-Branch Block
Interventions: Optimization of CRT Device; Diagnostic Test
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 89 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Little Rock, Arkansas • Detroit, Michigan

Conditions: Ametropia
Interventions: senofilcon A with new UV blocker, senofilcon A; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Statesboro, Georgia

Conditions: Lysosomal Storage Diseases, Cystinosis
Interventions: CTNS-RD-04 (including CTNS-RD-04-LB manufactured with LentiBOOST); Genetic
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Bladder Cancer, Urinary Bladder Neoplasm, Urologic Neoplasms, Neoplasms, Urinary Bladder Diseases
Interventions: Fiducial marker placement, Multiparametric MRI (mpMRI); Procedure · Diagnostic Test
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Los Angeles, California • Boston, Massachusetts

Conditions: Healthy
Interventions: Seltorexant 40 mg, Seltorexant 20 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy
Interventions: ibuzatrelvir, carbamazepine ER; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: Enlicitide, Digoxin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Hoarding Disorder, Attentional Impairment
Interventions: Cognitive Remediation, Control (Placebo); Behavioral
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Musculoskeletal Pain, Fibromyalgia, Healthy Controls Group - Age and Sex-matched
Interventions: S-cone modulating visual stimulus, Equal Energy White Visual Stimulus, Green light visual stimulus (S-OFF), Evoked Pressure Pain Stimulus; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Bioequivalence
Interventions: Treatment A: Acalabrutinib tablet, Treatment B: Acalabrutinib capsule; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 3
States / cities: Glendale, California • Brooklyn, Maryland • Salt Lake City, Utah

Search by objective public record fields.

A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy Subjects

Feasibility of Breathwork Intervention With Older Adults After Knee Surgery

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP

Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 (PASC) Using TSPO Positron Emission Tomography (PET) and MRI

The COSMYC Trial (COmbined Suppression of MYC)

Safety and Pharmacokinetics (PK) Study of Natrunix in Healthy Volunteers

Improving Sleep Using Mentored Behavioral and Environmental Restructuring

A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee

Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol

Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects

Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules

Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis

Massage: Neuroimaging and Correlates of Response - 1-week Study

Opto-electrical Cochlear Implants

Adaptive Cardiac Resynchronization Therapy in Patients With RBBB

The Effects of Contact Lenses With Experimental Dye on Visual Function

Stem Cell Gene Therapy for Cystinosis

Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy

A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions

A Study to Learn If the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine Ibuzatrelvir in Healthy Adults

A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031)

Cognitive Remediation for Neuropsychological Impairment in Compulsive Hoarding

Neural Mechanisms of Light Driven Analgesia

Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule